BioVie reports topline Phase 2 SUNRISE-PD results for bezisterim in early Parkinson's diseaseAug 6Clinical readoutbezisterimBiovie Inc.
BioVie files S-1 for stock offering, discloses Phase 2b Parkinson's topline timingJul 17FinancingBiovie Inc.
Sign in